SKLB-850

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameSKLB-850
Drug Alias NameSKLB-850
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitorsTyrosine-protein kinase SRC inhibitorsTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK2Spleen tyrosine kinaseTyrosine-protein kinase SRC
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesSichuan University
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A